Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 10/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.87 |
| ▸ | LMNA | P02545 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | PDE4A | P27815 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.87 |
| ▸ | DRD1 | P21728 | 1/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethaverine SCHEMBL29355739 | 0.93 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL29500886 | 0.93 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL25606 | 0.93 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL30417501 | 0.92 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL317507 | 0.92 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL17603566 | 0.92 | PDE3A (0.97) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL16180359 | 0.92 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL9614397 | 0.92 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL29624566 | 0.92 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Papaverine SCHEMBL9551009 | 0.92 | PDE10A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE3A 49/4885SMN1; SMN2 6/4885CYP3A4 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.